Eli Lilly has cut the price of its weight-loss drug Zepbound to $299 a month for the 2.5 mg dose, available through LillyDirect, matching recent cuts by rival Novo Nordisk for Wegovy. The move comes amid intensifying competition in the obesity drug market. Lilly shares dipped nearly 1% in pre-market trading as bearish sentiment rose on Stocktwits.